These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 1850611)
1. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Henry JA; Piggott NH; Mallick UK; Nicholson S; Farndon JR; Westley BR; May FE Br J Cancer; 1991 Apr; 63(4):615-22. PubMed ID: 1850611 [TBL] [Abstract][Full Text] [Related]
2. Expression of the oestrogen regulated pNR-2 mRNA in human breast cancer: relation to oestrogen receptor mRNA levels and response to tamoxifen therapy. Henry JA; Nicholson S; Hennessy C; Lennard TW; May FE; Westley BR Br J Cancer; 1990 Jan; 61(1):32-8. PubMed ID: 2153395 [TBL] [Abstract][Full Text] [Related]
3. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Henry JA; Bennett MK; Piggott NH; Levett DL; May FE; Westley BR Br J Cancer; 1991 Oct; 64(4):677-82. PubMed ID: 1911216 [TBL] [Abstract][Full Text] [Related]
4. Expression of the pS2 peptide in primary breast carcinomas: comparison of membrane and cytoplasmic staining patterns. Dookeran KA; Rye PD; Dearing SJ; Walker RA J Pathol; 1993 Oct; 171(2):123-9. PubMed ID: 8283349 [TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Cappelletti V; Coradini D; Scanziani E; Benini E; Silvestrini R; Di Fronzo G Eur J Cancer; 1992; 28A(8-9):1315-8. PubMed ID: 1515241 [TBL] [Abstract][Full Text] [Related]
6. Correlation of pS2 expression of involved lymph nodes in relation to primary breast carcinoma. Nichols PH; Ibrahim NB; Padfield CJ; Cawthorn SJ Eur J Surg Oncol; 1995 Apr; 21(2):151-4. PubMed ID: 7720888 [TBL] [Abstract][Full Text] [Related]
7. pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients. Soubeyran I; Quénel N; Coindre JM; Bonichon F; Durand M; Wafflart J; Mauriac L Br J Cancer; 1996 Oct; 74(7):1120-5. PubMed ID: 8855985 [TBL] [Abstract][Full Text] [Related]
8. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors. Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486 [TBL] [Abstract][Full Text] [Related]
9. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of the estrogen regulated pS2 protein in mammary tumors. Pichon MF; Milgrom E Crit Rev Oncol Hematol; 1993 Aug; 15(1):13-21. PubMed ID: 8240704 [TBL] [Abstract][Full Text] [Related]
11. [Analysis of the cytosolic content of the pS2 protein in breast cancer]. Tamargo F; Vizoso F; Lamelas ML; Rodil A; Vérez P; Raigoso P; Mulero M; Vázquez J; Roiz C; Allende MT Rev Esp Med Nucl; 2002 Feb; 21(1):28-33. PubMed ID: 11820999 [TBL] [Abstract][Full Text] [Related]
12. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases. Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Luqmani YA; Campbell T; Soomro S; Shousha S; Rio MC; Coombes RC Br J Cancer; 1993 Apr; 67(4):749-53. PubMed ID: 8385977 [TBL] [Abstract][Full Text] [Related]
14. High positive rate of pS2 expression in forefront intraductal cancerous area in breast cancer. Yamakawa T; Morimoto T; Sasa M; Numoto S; Monden Y Jpn J Cancer Res; 1995 Nov; 86(11):1035-40. PubMed ID: 8567393 [TBL] [Abstract][Full Text] [Related]
15. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Hurlimann J; Gebhard S; Gomez F Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242 [TBL] [Abstract][Full Text] [Related]
16. Antipeptide antibodies against the pNR-2 oestrogen-regulated protein of human breast cancer cells and detection of pNR-2 expression in normal tissues by immunohistochemistry. Piggott NH; Henry JA; May FE; Westley BR J Pathol; 1991 Feb; 163(2):95-104. PubMed ID: 1707960 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours. Pallud C; Le Doussal V; Pichon MF; Prud'homme JF; Hacene K; Milgrom E Histopathology; 1993 Sep; 23(3):249-56. PubMed ID: 8225243 [TBL] [Abstract][Full Text] [Related]
18. pS2 expression in infiltrating ductal carcinoma of the breast correlates with oestrogen receptor positivity but not with histological grade and lymph node status. Looi LM; Azura WW; Cheah PL; Ng MH Pathology; 2001 Aug; 33(3):283-6. PubMed ID: 11523925 [TBL] [Abstract][Full Text] [Related]
19. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778 [TBL] [Abstract][Full Text] [Related]
20. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]